Revenue
0 USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
INVECH HOLDINGS, INC.
EDGARAnnual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.
Latest quarter
Operating cash flow
-39.7 thousand USD
2026 Q2 · USD
Exact inputs and evidence
- Operating Cash Flow: -39692 USD Source
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 116 million shares Source
Exact value
115893597 shares
Reported share-count change
15.29% · 15.4 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
0 USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Net income
-222 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
-98.3 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -50447 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -39120 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -58258 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -50447 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -39500 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -39692 USD · 2026-04-01 – 2026-06-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-21.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2025-12-31
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- Current assets: 1 of 11 periods available· newest 2025-12-31
- Current liabilities: 1 of 11 periods available· newest 2025-12-31
- cash and cash equivalents: No compatible figures in this window
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
USD 0Prior period
USD 0
–
Current period
USD 0
–
Exact inputs and evidence
0 − 0 = 0 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2,457Prior period
−USD 60,475
–
Current period
−USD 58,018
–
Exact inputs and evidence
-58018 − -60475 = 2457 USD
-60475 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-58018 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3,477Prior period
−USD 61,735
–
Current period
−USD 58,258
–
Exact inputs and evidence
-58258 − -61735 = 3477 USD
-61735 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-58258 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 0
- Operating costs Derived USD 58,018
- Operating income −USD 58,018
- Tax, interest and other Derived USD 0
- Net income −USD 58,018
Cash
- Operating cash flow −USD 58,258
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2024 Not shown: operating income or net income is not reported.
- 2025 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | 0 | 60475 Derived | -60475 | 0 Derived | -60475 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 0 | 58018 Derived | -58018 | 0 Derived | -58018 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 0 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Revenue | 0 |
|
| 2025 | Revenue | 0 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Operating margin | Not reported |
|
| 2025 | Operating margin | Not reported |
|
| 2024 | Net margin | Not reported |
|
| 2025 | Net margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -58.3K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Operating cash flow | -61735 |
|
| 2025 | Operating cash flow | -58258 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
4,243.3% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Liabilities / assets | 780.5% |
|
| 2025 | Liabilities / assets | 4,243.3% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
0.02× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2025 | Current assets / current liabilities | 0.02× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 64,641 Exact valueExact value: -64641 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 63,641 Exact valueExact value: -63641 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 60,475 Exact valueExact value: -60475 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 61,735 Exact valueExact value: -61735 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 58,018 Exact valueExact value: -58018 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 58,258 Exact valueExact value: -58258 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
49 filings · 454 latest values · 454 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001009919, 1009919, IVHI, edgar:1009919
Also known as Amersin Life Sciences CORP, EXPLORE TECHNOLOGIES INC, HUBEI PHARMACEUTICAL GROUP LTD, INVECH HOLDINGS, INC., Invech Holdings, Inc., PAN ASIA COMMUNICATIONS CORP